Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Enliven Therapeutics, Inc. (IMRA)
|
Add to portfolio |
|
|
|
| Price: |
$2.39
| | Metrics |
| OS: |
41.2
|
M
| |
|
|
| Market cap: |
$98.4
|
M
| |
|
|
|
Net cash:
|
$126
|
M
| |
$3.05
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 0.0 | 8.2 |
| Revenue growth | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 10.7 |
| Gross profit | 0.0 | 0.0 | -2.4 |
| Gross margin | | | -29.6% |
| Research and development | 32.2 | 19.0 | |
| General and administrative | 9.5 | 5.1 | 2.4 |
| EBIT | -41.7 | -24.1 | -10.7 |
| EBIT margin | | | -129.6% |
| Pre-tax income | -41.4 | -23.5 | -11.3 |
| Income taxes | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% |
| Net income | -41.4 | -23.5 | -11.3 |
| Net margin | | | -137.6% |
| |
| Diluted EPS | ($2.97) | ($33.40) | ($0.02) |
| Shares outstanding (diluted) | 13.9 | 0.7 | 702.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|